1-methyl-4-(8-methylsulfanylspiro[6,7-dihydro-5H-1-benzothiepine-2,3'-cyclobutene]-6-yl)piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-methyl-4-(8-methylsulfanylspiro[6,7-dihydro-5H-1-benzothiepine-2,3'-cyclobutene]-6-yl)piperazine
• 化学式: C₁₉H₂₆N₂S₂
• 分子量: 346.6
• InChiKey: GGGSCFDLNLFLTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  57.1
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY
  申请人：Institut De Recerca Contra La Leucemia Josep Carreras

  公开号：EP3160472A1

  公开（公告）日：2017-05-03
• [EN] TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS<br/>[FR] TRAITEMENT DES MALADIES ET DES TROUBLES ASSOCIÉS À UNE HYPERACTIVITÉ DE MTOR
  申请人：BRIGHAM AND WOMEN S HOSPTIAL INC

  公开号：WO2014098932A1

  公开（公告）日：2014-06-26

  Embodiments disclosed herein provide combinatorial compositions and methods for treating cancer having deregulated mTOR signaling or mTOR hyperactivity, e.g., lymphangioleiomyomatosis (LAM), LAM/TSC or treating and/or management of tuberous sclerosis complex (TSC) using combination drug therapy comprising rapamycin and at least one of SCH-202676 hydrobromide, danusertib (PHA-739358), AZ-960, SB-590885, Thimerosal, ionomycin, U-73343, PAF C16, BX912, and Chlorambucil. In addition, methods for treating cancer having deregulated mTOR signaling or mTOR hyperactivity, or treating and/or management of tuberous sclerosis complex (TSC) using other known drugs are provided.
• [EN] METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY<br/>[FR] PROCÉDÉS POUR LE TRAITEMENT, LE DIAGNOSTIC ET LE PRONOSTIC D'UNE TUMEUR MALIGNE HÉMATOLOGIQUE
  申请人：INST RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS

  公开号：WO2015197839A1

  公开（公告）日：2015-12-30

  The invention relates to a serotonin receptor (5-HTR) inhibitorselected from the group consisting of a type 1 5-HTR inhibitorand a type 2 5-HTR inhibitorfor use in the prevention and/or treatment of a haematological malignancy. Additionallly, the invention relates to in vitromethods for the identificationor isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR.Furthermore, the invention relates to in vitromethods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type1 5-HTRand/or type 2 5-HTR.